Subcutaneous Treprostinil is Well Tolerated with Infrequent Site Changes and Analgesics-Reference-Cited by-同舟云学术

Subcutaneous Treprostinil is Well Tolerated with Infrequent Site Changes and Analgesics

Published:2013-09 Issue:3 Volume:3 Page:611-621
ISSN:2045-8940
Container-title:Pulmonary Circulation
language:en
Short-container-title:Pulm. circ.

Author:

White R. James¹,Levin Yana¹,Wessman Kathleen¹,Heininger Antonia¹,Frutiger Karen¹

Affiliation:

1. Mary Parkes Center for AsthmaAllergy, and Pulmonary CareDepartment of Pulmonary and Critical Care MedicineUniversity of RochesterRochesterNew YorkUSA

Funder

United Therapeutics Corporation

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1086/674304

Reference33 articles.

1. New predictors of outcome in idiopathic pulmonary arterial hypertension;Kawut SM;Am J Cardiol,2005

2. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long‐Term Pulmonary Arterial Hypertension Disease Management (REVEAL);Benza RL;Circulation,2010

3. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension;Humbert M;Eur Respir J,2010

4. Survival in patients with idiopathic, familial, and anorexigen‐associated pulmonary arterial hypertension in the modern management era;Humbert M;Circulation,2010

5. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of a randomized trial;Rubin LJ;Ann Int Med,1990

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cannabidiol (CBD) for the treatment of subcutaneous treprostinil (Remodulin®) site pain: a case report;Frontiers in Medicine;2023-06-13

2. Failure to tolerate continuous subcutaneous treprostinil in pediatric pulmonary hypertension patients;Pulmonary Circulation;2023-04

3. Long-Term Safety, Outcome, and Clinical Effects of Subcutaneous and Intravenous Treprostinil Treatment in Patients with Severe Chronic Pulmonary Arterial Hypertension;Respiration;2023

4. Real‐world dosing characteristics and utilization of parenteral treprostinil in the outpatient setting;Pulmonary Circulation;2022-01

5. Aggressive Afterload Lowering to Improve the RV: A New Target for Medical Therapy in PAH?;American Journal of Respiratory and Critical Care Medicine;2021-12-14